VeriSci received Phase I and Phase II SBIR grants from the National Institutes of Health to develop and commercialize devices for use in clinical settings:
Glaucoma early detection and monitoring
VeriSci has received funds from the National Eye Institute (NEI) of the NIH for development of a commercial device for quick assessment of early-stage glaucoma. The clinical test result was reported in the following article:
Zemon, V., Tsai, J.C., Forbes, M., Al-Aswad, L., Chen, C.M., Dhrami-Gavazi, E., Gordon, J., Greenstein, V., Hu, G., Strugstad, E.C., Jindra, L.F. Novel electrophysiological instrument for rapid and objective assessment of magnocellular deficits associated with glaucoma. Doc. Ophthal., 2008, 117, 233-243.
A multi-site study on early-stage glaucomatous damage has been completed in collaboration with scientists and clinicians at Columbia University Medical Center, Yale University School of Medicine, University of Tennessee Health Science Center, University of Virginia School of Medicine, and the University of Alabama at Birmingham School of Optometry.
The test for assessment of visual neural development in infants and young children employs a rapid sweep of stimuli (bars of different widths – different spatial frequencies) to efficiently and objectively measure neural mechanisms of spatial vision. Currently, the Neucodia system is used by leading clinicians and scientists for intensive clinical studies on visual disorders in infants and young children’s.
A clinical study on early-stage diabetic retinopathy has been conducted in collaboration with scientists and clinicians at Yale University School of Medicine. The result has been submitted for publication.
Biomarker for schizophrenia
VeriSci has received funds from the National Institute of Mental Health (NIMH) of the NIH for the development of a commercial device to serve as an electrophysiological biomarker for schizophrenia. Currently, clinical testing at the Nathan S. Kline Institute for Psychiatric Research, New York University (NYU) has been completed. The results will be submitted soon for publication. The device includes a unique battery of tests, which includes ones recognized by NIMH as recommended for perceptual/cognitive assessment of individuals with schizophrenia.
“Clinical trial sheds light on glaucoma” – Interview at Yale Eye Center by Channel 8 News VeriSci’s clinical study at Yale Eye Center for the detection of early-stage glaucoma using our innovative icVEP technology was reported by Channel 8 News http://www.wtnh.com/dpp/news/health/clinical-trial-yale-glaucoma